Basilea Pharmaceutica Ag
(OTC) BPMUF
Basilea Pharmaceutica Ag Financials at a Glance
Market Cap
$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
CHF 441.00M
Net Income (TTM)
CHF 117.80M
EPS (TTM)
$3.67
P/E Ratio
15.13
Dividend
$0.00
Beta (Volatility)
-0.01 (Low)
Dividend
$0.00
Beta (Volatility)
-0.01 (Low)
Price
$60.28
Volume
12
Open
$60.28
Price
$60.28
Volume
12
Open
$60.28
Previous Close
$60.28
Daily Range
$60.28 - $60.28
52-Week Range
$59.29 - $74.00
Estimated Earnings Date
Aug 18, 2026
Dividend
$0.00
Beta (Volatility)
-0.01 (Low)
Price
$60.28
Volume
12
Open
$60.28
Previous Close
$60.28
Daily Range
$60.28 - $60.28
52-Week Range
$59.29 - $74.00
Estimated Earnings Date
Aug 18, 2026
BPMUF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Basilea Pharmaceutica Ag
Industry
Biotechnology
Sector
Health CareEmployees
189
CEO
David Veitch
Website
www.basilea.comHeadquarters
Allschwil, BL 4058, CH
BPMUF Financials
Key Financial Metrics (TTM)
Gross Margin
74.32%
Operating Margin
21.94%
Net Income Margin
17.90%
Return on Equity
27.95%
Return on Capital
23.77%
Return on Assets
11.45%
Earnings Yield
6.61%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
12.40M
Volume
12
Avg. Volume
0.936
Financials (TTM)
Gross Profit
CHF 324.72M
Operating Income
CHF 112.79M
EBITDA
CHF 120.81M
Operating Cash Flow
CHF 136.47M
Capital Expenditure
-CHF 4.41M
Free Cash Flow
CHF 132.06M
Cash & ST Invst.
CHF 162.41M
Total Debt
CHF 89.22M
Basilea Pharmaceutica Ag Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
CHF 128.50M
+76.7%
Gross Profit
CHF 113.42M
+102.8%
Gross Margin
88.27%
N/A
Market Cap
$747.28MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$4.56M
N/A
Employees
164
N/A
Net Income
CHF 24.41M
+214.1%
EBITDA
CHF 29.37M
+833.8%
Quarterly Fundamentals
Total Cash
CHF 162.41M
+171.1%
Total Debt
CHF 89.22M
-30.6%
Accounts Receivable
CHF 63.31M
+127.0%
Inventory
CHF 21.57M
-18.3%
Long Term Debt
CHF 87.16M
-21.5%
Short Term Debt
CHF 2.06M
-88.2%
Return on Assets
11.45%
N/A
Return on Invested Capital
17.00%
N/A
Free Cash Flow
CHF 36.75M
+544.7%
Operating Cash Flow
CHF 39.05M
+612.6%